DEF: Centene Navigates 2025 Challenges, Eyes 40%+ EPS Growth in 2026

Centene Corporation faced significant disruption in 2025 with a GAAP diluted loss per share of $(13.53) and adjusted diluted EPS of $2.08, but anticipates over 40% growth in 2026, targeting adjusted diluted EPS exceeding $3.00.

Summary

• Centene experienced material disruption in 2025, including volatility in Medicaid trends and a significant shift in the Health Insurance Marketplace risk pool, leading to a lowered financial outlook in July.
• The company closed 2025 with a GAAP diluted loss per share of $(13.53) and adjusted diluted earnings per share (EPS) of $2.08, which was modest compared to the initial outlook but slightly ahead of October expectations.
• Management responded decisively by exiting certain programs that did not meet risk and return thresholds, prioritizing disciplined execution over short-term growth.
• For 2026, Centene expects improving fundamentals across its portfolio, including Medicaid margin stabilization, meaningful recovery in Marketplace margins, and continued progress toward breakeven in Medicare Advantage.
• The company projects full-year 2026 adjusted diluted EPS to exceed $3.00, representing more than 40% year-over-year growth, as it focuses on restoring embedded earnings power.
• Strategic priorities include strengthening agility, deepening operational focus (e.g., double-digit improvements in blood pressure and diabetes control, 93.3% customer satisfaction), and investing in modernization (technology, data, analytics, fraud prevention).
• Centene is the nation's largest Medicaid and Marketplace insurer and the largest stand-alone Medicare Prescription Drug Plan (PDP) provider, with $194.8 billion in 2025 premium and service revenues and 27.6 million members as of December 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with cautious optimism. While 2025 results were significantly negative, management's decisive actions and clear 2026 growth projections provide a path to recovery, though execution risks remain high.

Positives

• Improved execution in the fourth quarter of 2025 led to results slightly ahead of expectations provided to investors in October.
• Anticipates improving fundamentals across the portfolio in 2026, including Medicaid margin stabilization, meaningful recovery in Marketplace margins, and continued progress toward breakeven in Medicare Advantage.
• Expects full-year 2026 adjusted diluted EPS to exceed $3.00, representing more than 40% year-over-year growth.
• Achieved $194.8 billion in total revenues for 2025, a 19% increase over 2024, with a 10% three-year compound annual growth rate.
• Delivered double-digit improvements in blood pressure and diabetes control across Medicaid, Medicare, and Marketplace since 2023, along with meaningful gains in maternal and child health.
• Reported 93.3% satisfaction and 94.5% full resolution from 2.9 million post-call survey respondents in 2025, indicating strong service quality.
• Identified and prevented over $38 million in likely fraudulent payments using data analytics and investigative techniques.
• Maintained an investment grade rating by two of the three major rating agencies.
• Repurchased 71.6 million shares from January 2023 through December 2025 and $189 million of par value Senior Notes in 2025.
• Successfully completed 11 divestitures since December 2021, generating over $5 billion in proceeds.

Negatives

• Experienced material disruption across multiple parts of the business in 2025, including volatility in Medicaid trends and a meaningful shift in the Marketplace risk pool.
• Lowered financial outlook in July 2025 due to a seismic shift in morbidity within the broader population served by Marketplace products.
• Reported full-year 2025 adjusted diluted EPS of $2.08, which was modest compared to the outlook at the start of the year.
• Recorded a GAAP diluted loss per share of $(13.53) for 2025.
• Experienced a three-year compound annual stock price decline of 21%.
• The 2023-2025 performance-based restricted stock unit awards resulted in no payout due to underperforming financial results and stock price.
• A stockholder proposal highlighted that Centene's stock fell from $74 in 2018 to $35 in late 2025, and plummeted over 40% in a single day in July 2025.
• The company withdrew its full-year earnings guidance in July 2025, prompted by data showing lower-than-expected market growth and higher morbidity in Marketplace plans, expecting a $1.8 billion reduction in risk-adjustment revenue and a $2.75 hit to adjusted EPS.
• Reported a second-quarter diluted loss per share of $(0.51) in 2025.
• Barclays cut its price target and Goldman Sachs issued a 'Sell' recommendation in late 2025.
• A class-action lawsuit was announced in August 2025, alleging the company misled investors and inflated enrollment numbers/underestimated patient health risks.
• Settlements totaling over $1 billion were reached with more than 20 states regarding allegations of overcharging Medicaid programs related to pharmacy benefit manager operations.

Risks

• Ability to design and price products that are competitive and/or actuarially sound.
• Ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical costs.
• Rate cuts, insufficient rate changes, or other payment reductions or delays by government payors affecting government businesses.
• Effect of social, economic, and political conditions, geopolitical events, and state and federal policies, including funding for government-sponsored healthcare programs.
• Changes in federal or state laws or regulations, including those related to the ACA and enhanced advance premium tax credits, which could reduce membership or profitability.
• Unanticipated increased healthcare costs due to changes in consumer and provider behaviors, inflation, and tariffs.
• Ability to maintain or achieve improvement in CMS Star ratings and other quality scores, which could impact revenue and future growth.
• Competition for providers, broker distribution networks, contract reprocurements, and organic growth.
• Ability to adequately anticipate demand and timely provide for operational resources to maintain service level requirements and comply with contracts and regulations.
• Disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in third-party vendor relationships.
• Impairments to real estate, investments, goodwill, and intangible assets.
• Changes in senior management, loss of key personnel, or inability to attract, hire, integrate, and retain skilled personnel.
• Membership and revenue declines or unexpected trends.
• Changes in healthcare practices, new technologies, and advances in medicine.
• Ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws.
• Changes in macroeconomic conditions, including inflation, interest rates, and volatility in financial markets.
• Negative public perception of the company and the managed care industry.
• Uncertainty concerning government shutdowns, debt ceilings, or funding.
• Difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings, or matters, including resolving claims or whether additional actions will be brought.
• Cyber-attacks or other data security incidents or failure to comply with applicable privacy, data, or security laws and regulations.

Future Outlook

Centene expects improving fundamentals across its portfolio in 2026, including Medicaid margin stabilization, meaningful recovery in Marketplace margins, and continued progress toward breakeven in Medicare Advantage. The company is positioned to deliver meaningful margin expansion and renewed adjusted diluted EPS growth, with full-year 2026 adjusted diluted EPS projected to exceed $3.00, representing over 40% year-over-year growth.

Management Comments

• "The past year marked a period of significant change for Centene — change that, while challenging, sharpened our focus and clarified our path forward."
• "We were disappointed to lower our financial outlook last July amid a seismic shift in morbidity within the broader population served by Marketplace products."
• "We acted decisively, communicated transparently, and prioritized disciplined execution over short-term growth."
• "As we move forward, Centene is a more focused company with a clearer strategic foundation."
• "Our core businesses — Medicaid, Medicare Advantage, and the Health Insurance Marketplace — remain strong, differentiated platforms serving complex, high-need populations and facilitating access to healthcare for millions of Americans."
• "We see significant embedded earnings power across the enterprise, and we are focused on restoring and sustaining it over time."
• "For 2026, we updated our Marketplace go-to-market strategy to better accommodate a higher-morbidity population while positioning the company to improve profitability."
• "Looking ahead to 2026, we expect improving fundamentals across the portfolio, including Medicaid margin stabilization, meaningful recovery in Marketplace margins, and continued progress toward breakeven in Medicare Advantage."
• "We expect full-year 2026 adjusted diluted EPS to exceed $3.00, representing more than 40% year-over-year growth, an important step toward restoring the enterprises embedded earnings power."

Industry Context

StockSavvy.ai notes that Centene's challenges in 2025, particularly the 'seismic shift in morbidity' within the Marketplace risk pool and volatility in Medicaid trends, reflect broader industry pressures on health insurers adapting to evolving healthcare demographics and regulatory environments. The strategic pivot towards rigorous pricing and risk management in Marketplace and Medicare Advantage, alongside advocacy for Medicaid rate increases, indicates a sector-wide focus on profitability and sustainability over pure growth, a trend observed across peers like UnitedHealth Group and Elevance Health. The company's continued investment in technology and data analytics aligns with industry efforts to enhance care management and operational efficiency.

Comparison to Industry Standards

• Centene's 2025 adjusted diluted EPS of $2.08 and GAAP diluted loss per share of $(13.53) represent a significant underperformance compared to many peers in the S&P Health Care Index, which generally experienced positive total shareholder returns during the period.
• The 3-year compound annual stock price decline of 21% for Centene contrasts sharply with the positive total shareholder return of the S&P Health Care Index, indicating substantial underperformance relative to the broader healthcare market.
• The projected 2026 adjusted diluted EPS growth exceeding 40% suggests an aggressive recovery plan, potentially aiming to close the performance gap with more stable and profitable competitors such as Cigna or Humana.
• Despite 2025 challenges, Centene's position as the #1 carrier in the Health Insurance Marketplace and the largest Medicaid Managed Care Organization highlights its dominant market share in government-sponsored programs, a segment that often faces unique regulatory and demographic pressures compared to commercial insurers.

Management Changes

Corporate Governance

Legal Proceedings

• A class-action lawsuit was announced in August 2025 against Centene and its executives, alleging the company misled investors by painting an overly optimistic picture of its financial health and future prospects, and inflated enrollment numbers and underestimated patient health risks between December 2024 and June 2025.
• More than 20 states have settled with Centene over allegations of overcharging Medicaid programs related to its pharmacy benefit manager operations, with these settlements amounting to over $1 billion.

Related Party Transactions

• Kenneth Burdick, a director, served as Executive Chairman of LifeStance Health Group, Inc. until March 14, 2026. Centene continued to pay LifeStance for behavioral health services in 2025 under contracts entered into prior to Mr. Burdick's affiliation with LifeStance, on arm's length terms.
• One executive officer had an immediate family member employed by Centene in 2025, earning total compensation above $120,000, with compensation and benefits consistent with other employees of the same level and responsibilities.

Stakeholder Impact

• Shareholders are directly impacted by the significant financial underperformance in 2025, including a GAAP loss and stock price decline, but also by the potential for substantial recovery in 2026. Corporate governance proposals, such as director elections and executive compensation, directly affect shareholder rights and oversight.
• Employees are impacted by the company's talent and culture goals, the deployment of new engagement monitoring tools (Centene Voice), and the development of succession plans for critical roles. The launch of an employee ICHRA benefit also affects employee healthcare options.
• Customers and members are affected by the company's focus on quality improvement initiatives (e.g., blood pressure, diabetes, maternal/child health), service quality (93.3% satisfaction), and the implementation of the Duals Operating Model to ease care navigation for dual-eligible populations.
• Providers are impacted by Centene's efforts to strengthen relationships through responsive collaborations, streamlined interactions, and partnerships aimed at enhancing value-based care adoption.
• Government partners are engaged through advocacy for Medicaid rate increases and healthcare affordability. Past settlements over Medicaid overcharging allegations highlight regulatory scrutiny and financial implications for these partnerships.

Next Steps

• Hold the Annual Meeting of Stockholders on May 12, 2026, to elect directors, cast an advisory vote on executive compensation, and ratify the appointment of KPMG LLP as the independent registered public accounting firm.
• Continue strengthening strategic agility, deepening operational focus, and investing in modernization.
• Execute the updated Marketplace go-to-market strategy for 2026 to better accommodate a higher-morbidity population and improve profitability.
• Advocate with Medicaid state partners for increases in rates to reflect more recent experience.
• Implement the strategically designed 2026 Medicare Advantage bid and pricing strategy with a focus on profitability.
• Continue to advocate for healthcare affordability and access with state and federal government partners.
• Expand the employee Individual Coverage Health Reimbursement Arrangement (ICHRA) benefit, following a successful launch in Indiana.
• Recruit additional board candidates through a third-party director search firm.

Key Dates

Recommendation

Centene faces significant headwinds from 2025's underperformance, including a substantial GAAP loss and stock price decline, alongside ongoing legal challenges and negative analyst sentiment. However, management's aggressive strategic adjustments and a projected 40%+ adjusted EPS growth for 2026 suggest a potential turnaround. The stock is currently a "wait and see" as the company executes its recovery plan, making a hold recommendation appropriate for investors monitoring its progress and the effectiveness of its strategic shifts.

Keywords

Centene, Healthcare, Medicaid, Medicare Advantage, Health Insurance Marketplace, EPS, Financial Performance, Corporate Governance, Risk Management, Executive Compensation, Proxy Statement, SEC Filing